TEVA
Teva Pharma Industries Ltd
36.80$
+0.7%
vs. previous close
Closing price · As of: Aug 14, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 31.0% | 33.9% | 18.3% | 21.8% | 22.7% | 23.4% | 25.7% | 26.4% | 27.4% | 28.7% | 31.9% | 34.2% | |
| 4.8% | 12.8% | 1.1% | 1.4% | 2.9% | 3.4% | 4.3% | 4.5% | 6.4% | 7.4% | 8.4% | 8.7% | |
| 4.8% | 12.8% | 1.1% | 1.4% | 2.9% | 3.4% | 4.3% | 4.5% | 6.4% | 7.4% | 8.4% | 8.7% | |
| 11.7% | 9.9% | 8.1% | 10.1% | 9.6% | 9.9% | 9.0% | 9.5% | 8.4% | 7.8% | 7.8% | 9.1% | |
| 9.4% | 7.3% | 5.3% | 7.0% | 7.8% | 7.7% | 8.7% | 8.0% | 8.7% | 9.2% | 7.6% | 7.8% | |
| 14.1% | 12.1% | 8.0% | 10.9% | 11.3% | 11.2% | 12.4% | 12.5% | 14.0% | – | – | – | |
| 39.7% | 35.1% | 47.8% | 40.2% | 41.1% | 43.2% | 40.7% | 42.0% | 40.1% | 39.5% | 38.5% | 39.3% | |
| 11.9% | 14.1% | 23.1% | 25.0% | 23.1% | 19.5% | 17.6% | 15.7% | 14.2% | 12.4% | 11.2% | 9.3% | |
| 49.7% | 44.8% | 62.3% | 73.5% | 74.0% | 73.8% | 78.2% | 76.4% | 80.5% | 81.3% | 85.5% | 80.6% | |
| 26.5% | 24.0% | 19.9% | 25.4% | 23.6% | 23.8% | 26.0% | 23.1% | 26.1% | 28.2% | 32.5% | 33.0% | |
| 3.8% | 2.9% | 3.5% | 5.2% | 3.7% | 4.1% | 6.3% | 3.0% | 4.8% | 3.8% | 4.5% | 4.5% | |
| 6.8% | 3.5% | 2.3% | 2.9% | 3.1% | 3.0% | 3.5% | 3.5% | 4.3% | 6.0% | 5.6% | 6.2% | |
| 18.5% | 15.4% | 35.0% | 40.8% | 44.0% | 42.7% | 44.9% | 45.4% | 43.4% | 41.8% | 40.7% | 36.8% | |
| 50.2% | 54.9% | 35.9% | 24.6% | 24.2% | 24.3% | 19.8% | 21.6% | 17.7% | 17.3% | 13.7% | 19.4% | |
| 31.1% | 27.4% | 14.6% | -5.4% | -9.8% | -12.1% | -21.6% | -22.1% | -29.5% | -31.1% | -38.6% | -33.8% | |
| 1.8% | 1.6% | 1.0% | 1.4% | 1.7% | 1.9% | 2.2% | 2.3% | 2.5% | 2.6% | 2.9% | 2.9% |
Data as of: August 14, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.